Literature DB >> 18250636

Cardiometabolic features of polycystic ovary syndrome.

Leslie K Hoffman1, David A Ehrmann.   

Abstract

Polycystic ovary syndrome (PCOS) is a complex disorder comprising both hormonal and metabolic abnormalities that include impaired glucose tolerance, type 2 diabetes, vascular disease, dyslipidemia, and obstructive sleep apnea. Insulin resistance is a central pathogenetic factor in PCOS that seems to result from a post-receptor-binding defect in insulin action. Insulin resistance and the consequent development of hyperinsulinemia contribute to the constellation of cardiometabolic abnormalities noted above. Although there is a paucity of data in regard to cardiovascular event rates and mortality in PCOS, an increased prevalence of cardiovascular risk factors has been well documented. Attention to the metabolic risks associated with PCOS, starting as early as adolescence, is essential to the medical care of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250636     DOI: 10.1038/ncpendmet0755

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  24 in total

1.  Primary Prevention of Atherosclerotic Cardiovascular Disease in Women.

Authors:  Rebeccah A McKibben; Mahmoud Al Rifai; Lena M Mathews; Erin D Michos
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-12-29

Review 2.  The biology of gonadotroph regulation.

Authors:  Nick A Ciccone; Ursula B Kaiser
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-08       Impact factor: 3.243

Review 3.  GnRH pulse frequency-dependent differential regulation of LH and FSH gene expression.

Authors:  Iain R Thompson; Ursula B Kaiser
Journal:  Mol Cell Endocrinol       Date:  2013-09-19       Impact factor: 4.102

4.  Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome.

Authors:  Esra Tasali; Florian Chapotot; Rachel Leproult; Harry Whitmore; David A Ehrmann
Journal:  J Clin Endocrinol Metab       Date:  2010-12-01       Impact factor: 5.958

Review 5.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

6.  Excess androgen during puberty disrupts circadian organization in female rats.

Authors:  Michael T Sellix; Zachary C Murphy; Michael Menaker
Journal:  Endocrinology       Date:  2013-02-15       Impact factor: 4.736

Review 7.  Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Semin Reprod Med       Date:  2011-06-27       Impact factor: 1.303

8.  Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors.

Authors:  Nick A Ciccone; Shuyun Xu; Charlemagne T Lacza; Rona S Carroll; Ursula B Kaiser
Journal:  Mol Cell Biol       Date:  2009-12-14       Impact factor: 4.272

Review 9.  Animal models of the polycystic ovary syndrome phenotype.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Steroids       Date:  2013-05-20       Impact factor: 2.668

10.  Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease.

Authors:  Shrita M Patel; Sarah J Ratcliffe; Muredach P Reilly; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; Kim Sutton-Tyrrell; John Robbins; Linda P Fried; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2009-10-21       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.